Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A retrospective analysis of newly-diagnosed brain metastases in patients with breast cancer revealed that those with HER-2 positive disease had more favorable survival than those who were HER-2 negative. Compared to those with "triple negative" disease (median survival 4.0 months) those who had HER-2 positive disease survived 17.1 months.

HER-2 Status and Prognosis in Breast Cancer Patients with Brain Metastases